The Bull Case For Stryker (SYK) Could Change Following Mako RPS Handheld Knee Robotics Launch - Learn Why

• On 16 July 2026, Stryker launched Mako RPS (Robotic Power System) in the US, introducing Mako Handheld Robotics for total knee replacements that integrates intraoperative planning with a robotically enabled saw compatible with its Triathlon Total Knee System.
• This handheld expansion of the Mako ecosystem, designed to fit familiar surgical workflows and connect with the Q Guidance System, could broaden adoption of Stryker’s orthopaedic robotics across more surgeons and care settings.
• We’ll now explore how the new Mako RPS handheld platform, which extends Stryker’s orthopedic robotics reach, influences its investment narrative.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 29 companies in the world exploring or producing it. Find the list for free.

Stryker Investment Narrative Recap

To own Stryker, you need to believe its innovation in orthopaedic robotics and enabling technologies can deepen hospital relationships and support consistent growth. Mako RPS looks directionally positive for near term procedure adoption, but does not change the key catalysts around international product approvals or the ongoing risk from supply chain disruptions and cost inflation.

The recent European launch of the Pangea Plating System is especially relevant here, as it shows Stryker expanding its trauma and orthopaedics footprint abroad while Mako RPS broadens its robotics offering in the US. Together, these moves speak to the same core question for investors: how effectively Stryker can translate product breadth into sustained revenue growth while managing regulatory and pricing pressures.

But investors also need to be aware that persistent supply chain constraints and tariff exposure could still...

Read the full narrative on Stryker (it's free!)

Stryker's narrative projects $32.6 billion revenue and $6.5 billion earnings by 2029.

Uncover how Stryker's forecasts yield a $386.80 fair value, a 21% upside to its current price.

Exploring Other Perspectives

Seven fair value estimates from the Simply Wall St Community cluster between US$331 and US$406 per share, showing how far individual views can stretch. You can weigh those opinions against the company’s reliance on continued adoption of its Mako robotics ecosystem, which may shape how resilient its growth and profitability prove over time.

Explore 7 other fair value estimates on Stryker - why the stock might be worth just $331.44!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Stryker research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Stryker research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stryker's overall financial health at a glance.

Searching For A Fresh Perspective?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com